Remove Cardiovascular Disease Remove Cholesterol Remove Outcomes
article thumbnail

Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women

The New England Journal of Medicine

Measurement of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) predicted the 30-year cardiovascular disease risk among women enrolled in the Women’s Health Study.

article thumbnail

Novel PCSK9 Inhibitor Cut LDL Cholesterol Levels by More Than Half

DAIC

milla1cf Sun, 04/07/2024 - 18:09 April 7, 2024 — Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or “bad” cholesterol, levels by more than half on average, compared with a placebo.

article thumbnail

Inverted U?Shaped Association of Plasma Resolvin D2 With Atherosclerotic Cardiovascular Disease and the Mediation Effects of Serum Cholesterol: A Chinese Community?Based Study

Journal of the American Heart Association

The objective of this study was to examine the prospective association between plasma RvD2 and the risk of atherosclerotic cardiovascular disease (ASCVD) at the population level.Methods and ResultsA cohort of 2633 community‐dwelling individuals aged 35–60 years was followed for 8 years in this study. P<0.001).

article thumbnail

Harnessing RNA Interference for Cholesterol Lowering: The Bench?to?Bedside Story of Inclisiran

Journal of the American Heart Association

Lowering low‐density lipoprotein cholesterol (LDL‐C) is a cornerstone of reducing risk for atherosclerotic cardiovascular disease. Journal of the American Heart Association, Ahead of Print. Barriers include poor adherence, clinical inertia, concern for side effects, cost, and complex prior authorization processes.

article thumbnail

Impact of Bempedoic Acid on Total Cardiovascular Events

JAMA Cardiology

This prespecified analysis of the Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)–Inhibiting Regimen (CLEAR) Outcomes trial investigates if bempedoic acid is associated with a reduction in the total burden of cardiovascular events in patients at high risk for cardiovascular disease.

article thumbnail

Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia

Frontiers in Cardiovascular Medicine

AimsHistorically, atherosclerotic cardiovascular disease (ASCVD) risk profile mitigation has had a predominant focus on low density lipoprotein cholesterol (LDL-C). This relationship is complicated by the co-existence of low high-density lipoprotein cholesterol.

article thumbnail

Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study

Heart BMJ

Background Cardiovascular disease (CVD) risk increases with age. Statins reduce cardiovascular risk but their effects are less certain at older ages. CTTC individual participant data and other meta-analyses informed statins’ effects on cardiovascular risks, incident diabetes, myopathy and rhabdomyolysis.